Exelixis Stock: Mixed Signals After Earnings Beat

Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. The California-based firm reported earnings per share of $0.75, significantly outperforming analyst expectations of $0.64 by 17 percent. However, revenue came in at $568 million, falling short of the predicted $578.46 million. This discrepancy, along with 2025 revenue guidance of $2.25-2.35 billion (below consensus estimates), sent contradictory signals to the market. A dramatic decline in collaboration revenue contributed significantly to the revenue shortfall, plummeting from $199.6 million in the previous year to just $48.2 million this quarter – the absence of a $150 million milestone payment from the prior year created a challenging year-over-year comparison despite product revenue growth.

Pipeline Success Drives Future Opportunity

The company's Cabozantinib franchise continues showing impressive momentum, with US sales increasing 19 percent year-over-year to $520 million. The newly approved indication for neuroendocrine tumors has proven particularly successful, capturing approximately 35 percent market share in second-line oral treatments during its first full sales quarter. Meanwhile, Exelixis achieved a significant breakthrough with Zanzalintinib in the STELLAR-303 study for advanced colorectal cancer, where the combination with Atezolizumab demonstrated statistically significant overall survival improvement compared to standard treatment. With $1.4 billion in cash reserves and a refocused pipeline strategy, the company appears positioned to leverage these clinical successes despite the quarterly revenue disappointment.

Ad

Fresh Exelixis information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld